NewAmsterdam Pharma Company N.V.
NAMS
$0.65
Change (1 day)
$26.35
Year High
$5.63
Year Low
Categories
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V. (NAMS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 1.71 M | -309,311,907 | 53.34 M | 315.41 M | 315.13 M |
| 2022 | 1.94 M | -438,404,000 | 47.06 M | 531.58 M | 448.13 M |
| 2021 | 4.29 M | -52,928,000 | 9.99 M | 59.78 M | 58.87 M |
| 2020 | 3.79 M | 12.81 M | 9.23 M | 9.22 M |